<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhao Y</submitter><funding>National Natural Science Foundation of China</funding><pagination>146</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11494863</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>This study aims to assess the clinical efficacy of elective neck irradiation (ENI) in patients with esthesineuroblastoma (ENB), a rare malignant neoplasm, who are clinically node-negative.&lt;h4>Methods&lt;/h4>We conducted a retrospective analysis of 178 patients newly diagnosed with ENB at our institution between 2009 and 2021. Propensity score matching (PSM) was employed to compare node-negative patients treated with and without ENI. We extensively examined survival outcomes and treatment failure.&lt;h4>Results&lt;/h4>Of the 178 participants, 149 (83.7%) were lymph node-negative and staged in Modified Kadish A-C. 96 patients underwent ENI treatment, while 53 did not. At baseline, patients who received ENI differed from those who did not in terms of radiotherapy technique, staging,</pubmed_abstract><journal>Radiation oncology (London, England)</journal><pubmed_title>The value of elective neck irradiation in management of esthesioneuroblastoma: a retrospective study based on propensity score matching.</pubmed_title><pmcid>PMC11494863</pmcid><funding_grant_id>82303420</funding_grant_id><pubmed_authors>Yan L</pubmed_authors><pubmed_authors>Zhu Y</pubmed_authors><pubmed_authors>Li R</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>The value of elective neck irradiation in management of esthesioneuroblastoma: a retrospective study based on propensity score matching.</name><description>&lt;h4>Background&lt;/h4>This study aims to assess the clinical efficacy of elective neck irradiation (ENI) in patients with esthesineuroblastoma (ENB), a rare malignant neoplasm, who are clinically node-negative.&lt;h4>Methods&lt;/h4>We conducted a retrospective analysis of 178 patients newly diagnosed with ENB at our institution between 2009 and 2021. Propensity score matching (PSM) was employed to compare node-negative patients treated with and without ENI. We extensively examined survival outcomes and treatment failure.&lt;h4>Results&lt;/h4>Of the 178 participants, 149 (83.7%) were lymph node-negative and staged in Modified Kadish A-C. 96 patients underwent ENI treatment, while 53 did not. At baseline, patients who received ENI differed from those who did not in terms of radiotherapy technique, staging,</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Oct</publication><modification>2025-04-04T19:45:25.146Z</modification><creation>2025-04-04T19:45:25.146Z</creation></dates><accession>S-EPMC11494863</accession><cross_references><pubmed>39434155</pubmed><doi>10.1186/s13014-024-02539-x</doi></cross_references></HashMap>